Intellia to Present lonvo-z Phase 3 Data
Analysis based on 6 articles · First reported Jun 01, 2026 · Last updated Jun 01, 2026
The announcement of Phase 3 clinical trial data for Lonvoguran ziclumeran by Coya Therapeutics is expected to positively impact the company's stock price, as successful trials could lead to a new, potentially curative treatment for hereditary angioedema. This event also highlights the growing potential of CRISPR gene editing technology in the biotechnology and pharmaceutical industries.
Coya Therapeutics announced that data from its global Phase 3 HAELO clinical trial of Lonvoguran ziclumeran, a CRISPR-based gene editing therapy for hereditary angioedema (HAE), will be presented at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026 in Turkey — Istanbul, Turkey. Lonvoguran ziclumeran aims to be the first one-time treatment for HAE by permanently lowering kallikrein. The therapy has received multiple regulatory designations, including Orphan Drug and RMAT Designation from the United States — Food and Drug Administration, Innovation Passport from the United Kingdom — Medicines and Healthcare products Regulatory Agency, and PRIME and Orphan Drug Designation from the European Union — European Medicines Agency and International — European Commission, respectively. Dr. Danny Cohn will present the oral data, and Dr. Henriette Farkas will present a poster on HAE patient burdens.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard